Last modified: December 20, 2022
Quick Facts
  • certificate with a ribbon icon below
    • American Board of Internal Medicine, Medical Oncology & Hematology
  • plus sign in a circle icon
    • Hematology
    • Pleural Mesothelioma
    • Lung Cancer
    • Immunotherapy
    • Research

About Dr. Dudek

Medical oncologist Dr. Arkadiusz Dudek has been motivated for years by the challenge of improving cancer therapeutics, utilizing his expertise in cellular and molecular biology to better personalize treatment.

He was instrumental in developing the Metro-Minnesota Community Oncology Research Consortium, which has helped advance the treatment of malignant pleural mesothelioma through early-phase clinical trials.

Through his research, Dudek has played a significant role in the development of immunotherapy with several cancers and the synergistic effect when combining multiple agents.

Dudek was one of the first to explore the effectiveness of combining nivolumab and ramucirumab, also known as Opdivo and Cyramza, for previously treatment mesothelioma patients. He is leading another clinical trial involving durvalumab with chemotherapy for mesothelioma patients.

He is a firm believer that the recent FDA-approved combination of nivolumab and Ipilimumab has become a better first-line treatment option than the traditional chemotherapy for many patients.

Dudek also believes continued advancements with immunotherapy will soon make chemotherapy – and its often difficult side effects – obsolete in the treatment of most cancers.

Dr. Dudek’s Role as Medical Reviewer on

His extensive, oncological experience has made Dudek a perfect fit to medically review pages for The Mesothelioma Center at, the nation’s most trusted source of information on this rare cancer.

His research background also keeps him in tune with the latest, most up-to-date trends in medical oncology, making him an invaluable addition to the website.